8-K current report · filed Aug 13, 2026

CorMedix Inc. (CRMD) 8-K Current Report: August 13, 2026

Item EX-99.1Item 2.02CRMD overview

Short answer

CorMedix Inc. (CRMD) filed an 8-K current report with the SEC on August 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for quarter ended June 30, 2026.

CorMedix Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Investors should review Exhibit 99.1 for revenue, earnings, cash position and operating updates

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $101.9M, up from $39.7M, reflecting DefenCath sales $66.1M and Melinta portfolio contribution $35.8M
  • Net income $26.0M, diluted EPS $0.29, adjusted EBITDA $58.7M versus $22.4M year over year
  • FY 2026 revenue guidance maintained at $325M-$345M, while adjusted EBITDA guidance increased to $125M-$140M
  • New multi-year DefenCath agreement adds all top five U.S. dialysis providers, with pilot ordering beginning in Q3
  • Cash and short-term investments $256.7M, supporting commercial expansion and pipeline development without near-term funding pressure

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CorMedix Inc. 8-K filings

Get the next CRMD 8-K as it lands

Follow CRMD for push alerts, or ask the research agent what this filing means.